15n: Hsp110/HDAC6 Dual-Target Inhibitor Data for Pulmonary Arterial Hypertension

659.8 KB of research data from figshare details the rational design and testing of a novel dual-target inhibitor for pulmonary arterial hypertension. Author Mengqi Li published the data on 2026-05-11, describing the compound 15n, which targets Hsp110 and HDAC6 to synergistically block vascular remodeling. The dataset likely contains structure-activity relationship data and results from in vitro and in vivo experiments.

Use Cases

• Training predictive models for structure-activity relationships based on synthesized inhibitor compounds.
• Analyzing synergistic drug effects based on concurrent targeting of Hsp110 and HDAC6 pathways.
• Benchmarking new PAH drug candidates based on antivascular remodeling efficacy data.
• Studying the suppression of STAT3 signaling pathway based on dual-target inhibition.

Strengths

• Data is associated with a specific, promising lead compound (15n) identified through structure-activity relationship studies.
• The description details a clear biological mechanism of action involving synergistic blockade of two targets.

Limitations

• Row count is unknown, which may limit suitability assessment.
• Column-level documentation is absent; field semantics must be inferred after download.
• Description metadata is limited; actual data quality requires manual inspection after download.

Provenance

Source

figshare

Collection Method

Likely contains experimental data from rational drug design, synthesis, and biological assays.

Freshness

Last updated 2026-05-11 11:03:33; freshness should be verified.